Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Counsel

Benjamin Gossels

Goodwin Procter

main

Gossels Benjamin

Goodwin Counsel Benjamin Gossels, from Boston, practices in business law and tax among other areas. Learn more about Benjamin's experience & cases today.

Benjamin Gossels

Areas of Practice

Credentials

Education

JD2014

BA2011

Admissions

Bars

Related Content

Neighborhood Business Initiative | Little Cocoa Bean Co. in Boston, MA

The Best Lawyers in America 2025 Recognizes 312 Goodwin Lawyers

EQRx’s Acquisition by Revolution Medicines is Complete

The Best Lawyers in America 2024 Recognizes 320 Goodwin Lawyers Across 70 Practice Areas

EQRx To Be Acquired By Revolution Medicines In All-Stock Transaction

Berkshire Grey Enters Into Definitive Merger Agreement with SoftBank Group

Naver To Acquire Poshmark

Walgreens Boots Alliance Accelerates Full Acquisition of Shields Health Solutions for $1.37 Billion

Q32 Bio Collaborates with Horizon Therapeutics on Autoimmune Diseases, with up to $55 Million in Near-Term and $645 Million in Closing and Milestone Payments

Tax